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Abstract. 
A 56-year-old female presenting with vaginal bleeding and exertional dyspnea for 2 weeks 
was admitted to hospital. The clinical course and blood analysis revealed several uncommon 
signs of thrombotic microangiopathy: microangiopathic hemolytic anemia (schistocytes, de-
creased haptoglobin, and a negative direct Coombs’ test), thrombocytopenia, leukoerythro-
blastic blood film, creatinine, lactate dehydrogenase, and alkaline phosphatase were also ele-
vated. Bone marrow biopsy revealed metastatic infiltrating lobular carcinoma and focal bone 
marrow necrosis; and the primary lesion was subsequently identified in the right breast. We 
concluded that microangiopathic hemolytic anemia, thrombocytopenia, leukoerythroblastic 
blood film, lactate dehydrogenase, and alkaline phosphatase strongly indicated a disseminated 
malignancy with bone marrow involvement rather than thrombotic thrombocytopenic purpura 
or disseminated intravascular coagulation , which are also common in a disseminated malig-
nancy. In breast cancer cases with hematological signs, prompt the bone marrow examination is 
more improtant than tranditional systemic hormone or systemic chemotherapy or ineffective 
supportive treatment such as plasma exchange in order to obtain hematological repsonse. 
 
Keywords : infiltrating lobular carcinoma, thrombotic microangiopathy, microangiopathic 
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中文摘要 
  一名 56 歲的女性一開始表現為陰道出血和呼吸困難。血液相顯示血栓性微血管病
變：微血管病性溶血性貧血，血小板減少症，紅血球白血球芽細胞症，血清肌酸酐，乳
酸脫氫酶和鹼性磷酸酶也升高。骨髓病理切片顯示轉移性浸潤性乳房小葉癌和局部骨髓
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 壞死。原發病灶後來被確認為右乳房。我們的結論是血栓性微血管病變，紅血球白血球
芽細胞症，乳酸脫氫酶和鹼性磷酸酶升高的症狀表示骨髓轉移而不是血栓性血小板減少
性紫斑症或彌散性血管內凝血。如果有以上症狀應迅速做骨髓切片檢查，然後做積極賀
爾蒙治療或化療而不是支持性療法或無效的血漿置換，進而達到血液相的改善。 
 
關鍵字: 浸潤性乳小葉癌、血栓性微血管病變、微血管病性溶血性貧血、乳癌、
紅血球白血球芽細胞症 
INTRODUCTION 
Thrombotic microangiopathy (TMA) is a rare but 
serious disease characterized by microangiopathic he-
molytic anemia (MAHA), thrombocytopenia, and mi-
crovascular thrombotic lesions and end organ damage. 
TMA can be present among numerous syndromes, such 
as thrombotic thrombocytopenic purpura (TTP), hemo-
lytic uremia syndrome, neoplastic disease, pregnancy- 
associated and malignant hypertension, and also in 
medication-related effects. The association of cancer 
with TMA (CA-TMA), though not frequent, is either 
chemotherapy-related or due to some other cause such 
as bone marrow infiltration [1]. Bone marrow infiltra-
tion (i.e., myelofibrosis, myelophthisis), as well as 
severe bone marrow stress (i.e., severe sepsis, necro-
sis), are associated with a leukoerythroblastic blood 
film (nucleated red blood cells and the development of 
left-shifted granulopoietic elements, sometimes in-
cluding immature cells) in bones [2]. Although the 
hematological symptoms of CA-TMA may respond to 
anti-neoplastic agents, the overall prognosis remains 
poor. In this report, we describe a 56-year-old female 
who presented with TMA and a leukoerythroblastic 
blood film caused by breast cancer with bone marrow 
involvement. 
 
 
CASE REPORT 
A 56-year-old woman was admitted to our hospital 
presenting with vaginal bleeding and dyspnea for 2 
weeks. She had an indurated mass in the right breast, 
but did not want further diagnosis and treatment for it. 
Before we our physical examination, she didn't even 
mention of the breast mass. The physical examination 
showed pallor, fever, icteric sclera, and an indurated 
mass of the right breast with axillary lymphadenopa-
thy on the same side. The patient was diagnosed to 
have MAHA on the basis of laboratory findings, 
which included anemia (hemoglobin : 6.1 mg/dL, 
normal range: 12-14 mg/dl); with schistocytosis, pol-
ychromasia, and thrombocytopenia, as well as a leu-
koerythroblastic blood film (LEB; nucleated red blood 
cells and left shifted granulocytic elements). The dif-
ferential white blood cell count (WBC) was 19700/μL 
(normal range: 3600-10000/μL); seg, 56%; lympho-
cytes, 20%; band, 13%; myelocyte, 3%; promyelocyte, 
3%; meyloblast, 1%. Additional hematological find-
ings were platelets, 9000/μL (normal range: 140000- 
380000/μL); decreased haptoglobin (<6.6 mg/dL, 
normal range: 30-200 mg/dl), a negative direct 
Coombs’ test, and elevated serum total bilirubin (4.56 
mg/dL, normal range: 0.3-1.2 mg/dl ), mildly elevated 
creatinine (1.3 mg/dl , normal range: 0.4-1.0 mg/dl) 
and proteinuria (protein in urine analysis: 100 mg/dl, 
normal range: negative), lactate dehydrogenase (LDH) 
(1802 IU/L, normal range: 98-192 IU/L), and alkaline 
phosphatase ALK-P (462 IU/L, normal range: 32-91 
IU/L). The tumor markers levels including Ca-125 
(2292.1 U/mL, normal range: <35 U/ml ), carcinoem-
bryonic antigen (CEA) (134.3 ng/mL, normal range: 
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Figure 1. Bone marrow biopsy revealed metastatic 
carcinoma. It showed infiltration of nests 
or cords of tumor cells with hyperchro-
matic or vesicular nuclei and clear or eo-
sinophilic cytoplasm in the desmoplastic 
stroma. (hematoxylin and eosin stain, 
original magnification 200 ×) 
Figure 2. Core needle biopsy from the right breast 
showing infiltrating lobular carcinoma with 
similar morphology of marrow biopsy. 
(hematoxylin and eosin stain, original 
magnification 200 ×) 
 
 
 
 
<5 ng/ml), and Ca15-3 (1178.6 U/mL, normal range< 
31.3 U/ml) were all elevated. Prothrombin, partial 
thromboplastin, and fibrinogen levels were all within 
the normal range. Chest CT revealed an infiltrative 
mass in the subareolar region of the right breast and 
multiple reticular nodules with skin thickening and 
multiple enlarged lymph nodes in the right axilla. Ab-
dominal CT revealed diffuse osteoblastic lesion, but 
without lung or liver metastasis, and prominent en-
hancement over uterine endometium. A bone scan 
showed diffusely increased activity in most of the 
skeleton, suggesting bone metastasis. A bone marrow 
biopsy revealed nests or cords of infiltrating tumor 
cells with hyperchromatic or vesicular nuclei and clear 
or eosinophilic cytoplasm in desmoplastic stroma 
(Figure 1). Marrow necrosis was also evident. Im-
munostaining was positive for cytokeratin and the es-
trogen receptor but negative for E-cadherin. A core 
needle biopsy of the previously palpable right breast 
mass showed similar morphology (Figure 2) and im-
munostaining. The pathological finding of hyster-
oscopic myomectomy from the uterus also revealed 
metastatic infiltrating lobular carcinoma. An infiltrat-
ing lobular carcinoma of the right breast with bone 
marrow metastasis associated with TMA, bone mar-
row necrosis (BMN) and LEB was therefore diag-
nosed. We prescribed letrozole (2.5 mg QD), capecit-
abine (850 mg/m2 bid), and oral vinorelbine (80 
mg/m2 every week) , and blood-component treatment 
(Figure 3). The tumor marker levels markedly de-
creased and hemoglobin level and platelet count 
gradually improved. She was discharged 30 days after 
the initial presentation. We arranged chest CT scan 
three months later, which revealed a partial response 
in the breast mass as compared with the previous scan 
(tumor response definition according to RSCIST crite-
ria version 1.1). We kept oral chemotherapy until new 
liver metastasis occurred one year later. We changed 
the regimen to doxorubicin liposome (50 mg/m2 every 
month) monotherapy after the disease progress. 
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Figure 3. Summary of clinical course summary in this patient (PLT:platelet, Hb: hemoglobin) 
 
 
DISCUSSION 
Cancer is only rarely associated with thrombotic 
microangiopathy; the most common such tumors are 
gastric cancer (55%), breast cancer (13%), and lung 
cancer (10%), and the remainder are malignancies of 
unknown origin [3]. The pathogenesis of CA-TMA is 
complex and not well understood: endothelial injury, 
intraluminal tumor emboli, tumor-derived factors, 
DIC due to cancer-derived procoagulants, and chem-
otherapy agents have all been proposed as contributo-
ry factors [1]. CA-TMA patients respond to anti-tumor 
chemotherapy and have higher survival rates than pa-
tients without chemotherapy [4], and therefore early 
detection of disseminated malignancy and initiation of 
appropriate chemotherapy are very important [5]. In-
terestingly, CA-TMA is commonly accompanied by 
bone marrow infiltration [1,6]. Abnormal angiogensis 
in the marrow, aggressive growth of tumor and sec-
ondary myelofibrosis were mentioned and discussed 
in a previous study [6]. But in a study of 25 patients 
with bone marrow infiltration, only half had the typi-
cal TMA presentation [7]. Thus whether bone marrow 
infiltration is a cause of TMA needs to be further in-
vestigated. 
Diagnosis was challenging before the final patho-
logical report demonstrating malignancy in our patient, 
particularly in distinguishing her condition from TTP, 
DIC, or even hematological malignancy (based on the 
LEB). We presume that CA-TMA may exhibit some 
of the same characteristics as TTP. In most cases, TTP 
arises from deficiency of the enzyme ADAMTS13, a 
metalloprotease responsible for cleaving large multi-
mers of the von Willebrand factor. Plasmapheresis has 
become the treatment of choice for TTP. But our pa-
tient had clinical improvement after the anti-cancer 
regimen without plasmaphresis. Prothrombin, partial  
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 thromboplastin, and fibrinogen levels were all within 
the normal range in this patient. So we made the di-
agnose of CA-TMA rather than of TTP or DIC. 
TMA and LEB were the first presenting symptoms 
in our patient, without a tumor source identified prior 
to the pathological diagnosis of lobular breast cancer. 
Leukoerythroblastic reactions have been attributed to 
“crowding out” of marrow elements by tumor cells 
because of their interaction with hematopoietic cyto-
kines, and it occurs in 30-35% of non-hematological 
malignancies with bone marrow metastases [8]. Fur-
thermore, the combination of leukoerythroblastosis and 
TMA is highly suggestive of metastatic malignancy in 
the bone marrow [2,9]. Other confirmatory biochemis-
try findings were elevated LDH and high ALK-P [5,9]. 
Patients with disseminated malignancy involving the 
bone marrow typically have a very poor prognosis and 
survive for only a few days or weeks because of bone 
marrow failure induced bleeding tendency, infection, 
and high tumor burden according to previous case re-
ports. Treatment must be focused on primary tumors 
but a majority of patients receive supportive treatment 
only. Survival also can be affected by the tumor origin, 
but no studies have ever discussed discrepancy in out-
comes among different tumors. 
Chemotherapy for bone marrow metastases poses 
a treatment challenge because the various cytotoxic 
agents also have a suppressive effect on the bone 
marrow. Letrozole, capecitabine, and vinorelbine are 
now widely used to treat metastatic breast cancer. In 
our patient, we prescribed chemoendocrine therapy 
and achieved a good partial response. We initiated 
empiric hormone treatment (letrozole) for possible 
breast cancer prior to definitive tissue evidence. After 
the definitive diagnosis was made, we shifted to cape-
citabine and vinorelbine in an effort to avoid further 
severe bone marrow suppression. Vinorelbine has sig-
nificant activity against breast carcinoma and oral vi-
norelbine is generally well tolerated [10]. Capecita-
bine for metastatic breast cancer has a favorable safety 
profile, lacking myelosuppressive activity [11]. Ghons 
et al. reported that Navcap (vinorelbine and capecita-
bine) followed by Docetaxel regimens were tolerated 
with manageable toxicity, offering consistent activity 
in terms of the response rate [12]. Our patient did not 
require transfusion of blood components after chemo-
therapy and there was no ongoing anemia or bleeding 
tendency. The relatively long survival in our patient 
was probably attributable to the favorable hematolog-
ical responses to chemotherapy.  
Six patients of breast cancer with bone marrow 
metastasis treated at our hospital between 2002 and 
2011 were analyzed (Table 1). The hematological 
signs in our patients indicated microangiopathic ane-
Table 2. Hematological parameters of the patients at the time of diagnosis (case 6: present case) 
No WBC(/μL) Hb 
(g/dL) 
PLT 
(×10^3/μL) 
RDW
(%) 
Reticulocyte 
(/μL) 
ESR 
(mm/hr)
Coagulation 
(PT/APTT sec) 
LDH 
(U/L) 
ALK-P
(U/L) 
1 4700 4.5 4 28.7 67873 140 14/26.6 382 131 
2 6000 12.8 336 13.3 NA 69 10.2/25.9 N 124 
3 8100 8.1 62 23 64769 NA 11.7/27 350 143 
4 3800 8 120 15 NA NA NA 400 193 
5 2100 8.3 193 15 16350 NA NA 208 274 
6 19700 6.1 9 20.2 130788 381 11.3/27.8 1802 462 
Normal 
range  
3600- 
10000 
12-14 140000- 
380000 
11.7- 
14.9 
30000- 
70000 
<25 9.9-12/ 
28.6-38.6 
98- 
192 
32- 
91 
NA: not available 
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 mia and thrombocytopenia (3 out of 6 patients), LEB 
(5 out of 6 patients). Other confirmatory biochemistry 
findings were elevated LDH, elevated red cell distri-
bution (RDW), and high ALK-P (Table 2). All the pa-
tients had bone metastasis. One patient received sup-
portive treatment with short survival (2.1 months). 
Other patients received aggressive combination treat-
ment such as palliative radiotherapy, hormone therapy, 
oral chemotherapy, systemic chemotherapy. Two pa-
tients achieved complete hematological response 
(Definition: Hemoglobin>10 mg/dl, platelet> 100000 
μL, Transfusion independent for four weeks). The es-
timated median overall survival after the date of bone 
marrow metastasis diagnosed was 32.3 months (95% 
confidence level: 15.4-49.2 months), and 2 patients 
are still alive. Even with severe bone marrow failure 
due to bone marrow metastasis, aggressive combina-
tion treatment as improved marrow function is possi-
ble in 5 of our 6 patients. 
 
CONCLUSIONS 
We highlighted that aggressive treatment in breast 
cancer with bone marrow metastasis and received he-
matological response rather than traditional supportive 
treatment alone. Early detection of bone marrow me-
tastasis is mandatory in breast cancer, especially for 
such patients who present with unknown etiology of 
anemia, thrombocytopenia, leukoerythroblastosis, el-
evated RDW, AlK-P, LDH.  
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